Advanced lung adenocarcinoma with EGFR 19-del mutation transforms into squamous cell carcinoma after EGFR tyrosine kinase inhibitor treatment

Ruo-Bing Qi; Zheng-Hao Wu

doi:10.12998/wjcc.v12.i32.6543

Advanced lung adenocarcinoma with EGFR 19-del mutation transforms into squamous cell carcinoma after EGFR tyrosine kinase inhibitor treatment

World J Clin Cases. 2024 Nov 16;12(32):6543-6546. doi: 10.12998/wjcc.v12.i32.6543.

Authors

Ruo-Bing Qi¹, Zheng-Hao Wu²

Affiliations

¹ Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei Province, China.
² Department of Breast and Thyroid Surgery, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022, Hubei, China. [email protected].

Abstract

In this editorial we comment on the article by Ji et al. We focus specifically on the EGFR tyrosine kinase inhibitor (EGFR-TKI) treatment and the development of drug resistance to EGFR-TKIs.

Keywords: Drug resistance; Epidermal growth factor receptor tyrosine kinase inhibitor; Histological transformation; Lung adenocarcinoma; Squamous cell carcinoma.

Publication types

Editorial